Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment tags : Therapy save search
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy
Published: 2024-04-16 (Crawled : 12:00) - globenewswire.com
LXEO | $11.995 -0.62% -0.63% 87K
|
|
| O: 5.32%
H: 0.0%
C: -2.63%
lx2006 fda candidate granted treatment designation for therapeutics therapy
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
Published: 2024-04-09 (Crawled : 12:30) - prnewswire.com
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: 2.36%
H: 6.6%
C: 1.32%
reqorsa lung report positive treatment system preclinical for meeting therapy
CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy
Published: 2024-04-06 (Crawled : 04:20) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
carvykti fda first approved one treatment for therapy
Global Particle Therapy Market Analysis and Forecasts, 2023-2033 : Revolutionizing Cancer Treatment, Particle Therapy's Rise in External Beam Radiotherapy
Published: 2024-03-27 (Crawled : 23:00) - prnewswire.com
BSGM | $1.41 -8.44% -9.22% 200K
|
Health Technology
|
| O: 3.94%
H: 4.19%
C: -10.55%
cancer global therapy market
NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression
Published: 2024-03-25 (Crawled : 12:30) - globenewswire.com
STIM | $3.8 -0.78% -0.79% 49K
|
Health Technology
|
| O: 13.48%
H: 3.96%
C: -1.88%
neurostar fda depression treatment clearance advanced therapy
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee
Published: 2024-03-13 (Crawled : 11:00) - globenewswire.com
PCRX | $26.24 0.54% 0.53% 450K
|
Health Technology
|
| O: 0.03%
H: 1.24%
C: -0.92%
pcrx-201 osteoarthritis granted treatment designation therapy
MangoRx Officially Launches ‘PRIME’ by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) Treatment
Published: 2024-03-12 (Crawled : 13:00) - globenewswire.com
MGRX | $0.286 -4.64% -4.86% 78K
|
|
| O: -2.97%
H: 18.53%
C: 5.15%
kyzatrex fda approved treatment therapy
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
Published: 2024-03-06 (Crawled : 13:30) - prnewswire.com
GNPX | $2.2194 -2.31% 38K
|
Health Technology
|
| O: 24.27%
H: 5.66%
C: -14.45%
reqorsa lung positive treatment system preclinical meeting therapy
Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function
Published: 2024-03-06 (Crawled : 08:00) - globenewswire.com
BMEA | $10.87 -2.6% -2.67% 1.3M
|
Professional, Scientific, and T...
|
| O: -16.72%
H: 16.45%
C: 8.29%
alent-111 pancreatic treatment therapy
RYBREVANT® (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Published: 2024-03-01 (Crawled : 21:00) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
rybrevant fda first lung approved cancer cell treatment therapy
Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy
Published: 2024-02-23 (Crawled : 22:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.28%
H: 0.0%
C: 0.0%
LEGN | $46.14 -2.08% -2.12% 1.2M
|
Health Technology
|
| O: 2.07%
H: 5.02%
C: 4.92%
carvykti chmp biotech positive treatment therapy
Cell Therapy Company Tevogen Bio Holdings Inc. Prepares to Launch Crucial Genetic Predisposition Study in Preparation to Investigate the Potential of TVGN 489 to Address Critical Unmet Need for Long COVID Treatment
Published: 2024-02-21 (Crawled : 19:00) - biospace.com/
LGST | $4.51 -11.31% 13K
|
n/a
| Email alert
Add to watchlist
covid company genetic cell treatment potential therapy study
Johnson &Johnson's nipocalimab granted U.S. FDA Breakthrough Therapy Designation for the treatment of individuals at high risk for severe hemolytic disease of the fetus and newborn (HDFN)
Published: 2024-02-09 (Crawled : 14:30) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.68%
H: 0.0%
C: 0.0%
fda disease granted treatment risk designation therapy
Johnson & Johnson's nipocalimab granted U.S. FDA Breakthrough Therapy Designation for the treatment of individuals at high risk for severe hemolytic disease of the fetus and newborn (HDFN)
Published: 2024-02-09 (Crawled : 13:00) - prnewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.68%
H: 0.0%
C: 0.0%
fda disease granted treatment risk designation therapy
Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections
Published: 2024-02-07 (Crawled : 12:30) - prnewswire.com
COEP | $0.34 -3.13% -3.24% 190K
|
|
| O: -1.59%
H: 5.06%
C: -2.09%
cell treatment program infections therapeutics therapy
EDAP Announces Completion of Enrollment in Phase 3 Study Evaluating Focal One HIFU Therapy for the Treatment of Deep Infiltrating Rectal Endometriosis
Published: 2024-02-01 (Crawled : 13:00) - globenewswire.com
EDAP | $7.21 1.12% 1.11% 6.7K
|
Health Technology
|
| O: 1.2%
H: 0.0%
C: -5.79%
one treatment therapy study
Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
Published: 2024-01-25 (Crawled : 21:00) - globenewswire.com
RARE | News F | $42.37 -2.33% -2.38% 680K
|
Health Technology
|
| O: 0.55%
H: 1.01%
C: -1.16%
ux701 disease treatment therapy study
Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases
Published: 2024-01-09 (Crawled : 13:30) - biospace.com/
TGTX | $13.79 -1.43% -1.45% 3.7M
|
Health Technology
|
| O: -8.22%
H: 9.05%
C: 7.47%
DTIL | $9.75 -9.05% -9.95% 170K
|
Health Technology
|
| O: 10.0%
H: 14.23%
C: 0.09%
license cell treatment deal therapeutics therapy
TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision’s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases
Published: 2024-01-09 (Crawled : 12:00) - globenewswire.com
TGTX | $13.79 -1.43% -1.45% 3.7M
|
Health Technology
|
| O: -8.22%
H: 9.05%
C: 7.47%
DTIL | $9.75 -9.05% -9.95% 170K
|
Health Technology
|
| O: 10.0%
H: 14.23%
C: 0.09%
cd19 license cell treatment global commercialization program therapeutics agreement therapy
4DMT Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD, the First RMAT Designation in Wet AMD
Published: 2023-12-21 (Crawled : 13:00) - globenewswire.com
FDMT M | $25.29 2.06% 2.02% 630K
|
Health Technology
|
| O: 3.04%
H: 7.13%
C: 4.18%
fda rmat first genetic treatment designation advanced therapy
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.